黃 仁弘

Medicine & Life Sciences

1. Pulmonary Veins 100%
2. Atrial Fibrillation 90%
3. Cardiac Myocytes 61%
4. Sinoatrial Node 43%
5. Heart Atria 40%
6. Rivaroxaban 37%
7. Calcium 35%
8. Homeostasis 35%
9. Medical Order Entry Systems 34%
10. Action Potentials 34%
11. Supraventricular Tachycardia 28%
12. Peroxisome Proliferator-Activated Receptors 27%
13. Population 27%
14. Self-Management 24%
15. ST Elevation Myocardial Infarction 22%
16. Heart Rate 21%
17. Hospitalization 21%
18. Paroxysmal Tachycardia 21%
19. Stents 19%
20. Electrophysiology 17%
21. Simendan 17%
22. Factor Xa Inhibitors 17%
23. Heart Failure 16%
24. Parapharyngeal Space 16%
25. alternan 16%
26. Rabbits 16%
27. Sitagliptin Phosphate 16%
28. Electrocardiography 16%
29. Diabetic Cardiomyopathies 16%
30. Circulating MicroRNA 16%
31. Apamin 16%
32. Carvedilol 15%
33. Fenofibrate 15%
34. Randomized Controlled Trials 15%
35. Muscle Cells 15%
36. 1,25-dihydroxyvitamin D 15%
37. Phosphodiesterase Inhibitors 15%
38. Thrombomodulin 15%
39. Dipeptidyl-Peptidase IV Inhibitors 15%
40. Biomarkers 14%
41. Androgens 14%
42. Coronavirus 14%
43. Induced Hypothermia 14%
44. antineoplaston A10 14%
45. Amiodarone 13%
46. Cardiac Arrhythmias 13%
47. Blood Pressure 13%
48. AMP-Activated Protein Kinases 13%
49. Arginine Vasopressin 13%
50. ITI-214 13%